<DOC>
	<DOCNO>NCT02657252</DOCNO>
	<brief_summary>It do randomize triple-blind study compare 0,2 % polidocanol versus 75 % hypertonic glucose sclerotherapy lower limbs´ telangiectasis . It include adult woman reticular vein side thigh mild venous insufficiency ( CEAP 1 ) . The primary endpoint efficacy , secondary safety .</brief_summary>
	<brief_title>Polidocanol Versus Glucose Treatment Telangiectasia Trial</brief_title>
	<detailed_description>Background . The prevalence chronic venous disease high general population , mainly young woman , milder case usual complaint aesthetic . Various technique use treatment mild varicose disease , include surgical treatment , laser ablation sclerotherapy . Telangiectasis le 1 mm diameter , reddish important contribution aesthetic damage , sometimes related local pain . There consensus literature effectiveness treatment sclerotherapy , despite usual procedure different chemical . Methods design . One hundred low limbs healthy woman 18 65 year triple blind randomized receive treatment polidocanol 0.2 % dilute 70 % hypertonic glucose versus 75 % hypertonic glucose sclerotherapy treatment telangiectasis . The patient examine clinically classify . It include patient telangiectasis sit 's thigh , one extremity include per patient . The patient varicose disease CEAP 2 include . The treatment carry one session medication volume exceed 5 ml . Clinical follow-up protocol fill regular visit day 0 - 7 - 60 concomitantly photograph documentation . Supplementary examination venous map ultrasound pretreatment perform patient . Discussion . This prospective control double-blind randomize trial aim verify compare efficacy safety sclerotherapy treatment telangiectasis low limb . The result may help physician choose best sclerotherapy treatment telangiectasis .</detailed_description>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Polidocanol</mesh_term>
	<criteria>female telangiectasis thigh side clinical classification chronic venous disease C1 ( mild venous disease ) , minimum age 18 yearold maximum age 65 yearold agreement study sign free inform consent ( IC ) use anticoagulant drug . male varicose disease quantity location clinical classification chronic venous disease different C1 ( mild venous disease ) restrict mobility arterial insufficiency allergic substance may relate study drug cause dermatitis application site don´t free comorbidities clinically serious diabetes mellitus , heart failure , respiratory failure , uncontrolled hypertension medication , uncontrolled hypothyroidism pregnancy previous deep vein thrombosis ( DVT ) family history DVT thrombophilia agree search term</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>telangiectasis</keyword>
	<keyword>varicose vein</keyword>
	<keyword>vein</keyword>
	<keyword>glucose</keyword>
	<keyword>sclerotherapy</keyword>
</DOC>